File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Maternal immunization with a DNA vaccine candidate elicits specific passive protection against post-natal Zika virus infection in immunocompetent BALB/c mice

TitleMaternal immunization with a DNA vaccine candidate elicits specific passive protection against post-natal Zika virus infection in immunocompetent BALB/c mice
Authors
Issue Date2018
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
Citation
Vaccine, 2018, v. 36 n. 24, p. 3522-3532 How to Cite?
AbstractZika virus (ZIKV) infection is closely associated in the fetus with microcephaly and in the adults with Guillain-Barre syndrome and even male infertility. It is an urgent international priority to develop a safe and effective vaccine that offers protection to both women of childbearing age and their children. In this study, female immunocompetent BALB/c mice were immunized with a DNA-based vaccine candidate, pVAX1-ZME, expressing the prM/E protein of ZIKV, and the immunogenicity for maternal mice and the post-natal protection for suckling mice were evaluated. It was found that administration with three doses of 50mug pVAX1-ZME via in vivo electroporation induced robust ZIKV-specific cellular and long-term humoral immune responses with high and sustained neutralizing activity in adult mice. Moreover, using a maternal immunization protocol, neutralizing antibodies provided specific passive protection against ZIKV infection in neonatal mice and effectively inhibited the growth delay. This vaccine candidate is expected to be further evaluated in higher animals, and maternal vaccination shows great promise for protecting both women of childbearing age and their offspring against post-natal ZIKV infection. The vaccinated mothers and ZIKV-challenged pups provide key insight into Zika vaccine evaluation in an available fully immunocompetent animal model.
Persistent Identifierhttp://hdl.handle.net/10722/258946
ISSN
2023 Impact Factor: 4.5
2023 SCImago Journal Rankings: 1.342
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorWANG, R-
dc.contributor.authorLIAO, XZ-
dc.contributor.authorFAN, DY-
dc.contributor.authorWANG, L-
dc.contributor.authorSONG, J-
dc.contributor.authorHAO, KH-
dc.contributor.authorLi, M-
dc.contributor.authorWANG, PG-
dc.contributor.authorCHEN, H-
dc.contributor.authorAN, J-
dc.date.accessioned2018-09-03T03:58:52Z-
dc.date.available2018-09-03T03:58:52Z-
dc.date.issued2018-
dc.identifier.citationVaccine, 2018, v. 36 n. 24, p. 3522-3532-
dc.identifier.issn0264-410X-
dc.identifier.urihttp://hdl.handle.net/10722/258946-
dc.description.abstractZika virus (ZIKV) infection is closely associated in the fetus with microcephaly and in the adults with Guillain-Barre syndrome and even male infertility. It is an urgent international priority to develop a safe and effective vaccine that offers protection to both women of childbearing age and their children. In this study, female immunocompetent BALB/c mice were immunized with a DNA-based vaccine candidate, pVAX1-ZME, expressing the prM/E protein of ZIKV, and the immunogenicity for maternal mice and the post-natal protection for suckling mice were evaluated. It was found that administration with three doses of 50mug pVAX1-ZME via in vivo electroporation induced robust ZIKV-specific cellular and long-term humoral immune responses with high and sustained neutralizing activity in adult mice. Moreover, using a maternal immunization protocol, neutralizing antibodies provided specific passive protection against ZIKV infection in neonatal mice and effectively inhibited the growth delay. This vaccine candidate is expected to be further evaluated in higher animals, and maternal vaccination shows great promise for protecting both women of childbearing age and their offspring against post-natal ZIKV infection. The vaccinated mothers and ZIKV-challenged pups provide key insight into Zika vaccine evaluation in an available fully immunocompetent animal model.-
dc.languageeng-
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine-
dc.relation.ispartofVaccine-
dc.titleMaternal immunization with a DNA vaccine candidate elicits specific passive protection against post-natal Zika virus infection in immunocompetent BALB/c mice-
dc.typeArticle-
dc.identifier.emailLi, M: myli2014@hku.hk-
dc.identifier.doi10.1016/j.vaccine.2018.04.051-
dc.identifier.scopuseid_2-s2.0-85046655037-
dc.identifier.hkuros287932-
dc.identifier.volume36-
dc.identifier.issue24-
dc.identifier.spage3522-
dc.identifier.epage3532-
dc.identifier.isiWOS:000435060600020-
dc.publisher.placeUnited Kingdom-
dc.identifier.issnl0264-410X-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats